Caption
: Recruiting trial
= 
; Ongoing trial
= 
-
- BELGIUM
- ARRONDISSEMENT BRUSSELS-CAPITAL
- BRUSSELS
- CP4126-201 : A phase II study of CP-4126 in patients with advanced pancreatic cancer - BE
- Institut Jules Bordet
- More details
-
- BELGIUM
- ARRONDISSEMENT BRUSSELS-CAPITAL
- NOT YET IDENTIFIED - BE
- CP4126-201 : A phase II study of CP-4126 in patients with advanced pancreatic cancer - BE
- Not yet identified - BE
- More details
-
- FRANCE
- ILE-DE-FRANCE
- VILLEJUIF
- A phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma - FR
- CRLCC Institut de cancérologie Gustave Roussy
- Service de gastroentérologie
- More details
-
- FRANCE
- LANGUEDOC-ROUSSILLON
- MONTPELLIER
- (GATE 1) Phase II clinical trial evaluating the combination of gemcitabine, trastuzumab and erlotinib as first-line chemotherapy in patients with metastatic pancreatic adenocarcinoma .
- Parc Euromédecine
- ICM - Institut régional du Cancer Montpellier (Val d'Aurelle)
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Phase II randomized trial of MEK inhibitor AS703026 or placebo combined with gemcitabine in chemo-naive metastatic pancreas cancer subjects - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- FFCD 1004: Pharmacogenetics of Gemcitabine: Study of the Impact of Genetic Polymorphism of Cytidine Deaminase (CDA) on Toxicity in Resected Pancreatic Adenocarcinomas - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- EUROPEAN STUDY GROUP FOR PANCREATIC CANCER -TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic cancer - FR
- Not yet identified - FR
- More details
-
- GERMANY
- Baden-Württemberg
- ULM
- Phase II Study: docetaxel plus oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer
- Universitätsklinikum Ulm
- Klinik für Innere Medizin I
- More details
-
- HEAT - A Randomized, two-armed, open-label, phase III study on the adjuvant therapy in patients with R0/R1 resected Pancreatic Carcinoma with Gemcitabine alone (Arm G) versus Gemcitabine plus Cisplatin with regional hyperthermia (Arm GPH)
- LMU Klinikum der Universität München - Campus Großhadern
- Medizinische Klinik und Poliklinik III
- More details
-
- CONKO-005: A prospective, randomized phase III study of adjuvant therapy of R0-resectable Pancreatic Carcinoma with Gemcitabine plus Erlotinib versus Gemcitabine for 24 weeks
- Charité - Universitätsmedizin Berlin (CVK)
- Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- C-II-004: Phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
- Medizinische Klinik II - Hämatologie und Onkologie
- More details
-
- GERMANY
- Niedersachsen
- HANNOVER
- Tumor-vaccine therapy in pancreatic carcinoma - Terminated
- Medizinische Hochschule Hannover
- Klinik für Gastroenterologie, Hepatologie und Endokrinologie
- More details
-
- GERMANY
- Nordrhein-Westfalen
- HERNE
- Gemcitabine and Nimotuzumab (OSAG 101) versus Gemcitabine and placebo for the treatment of patients with metastatic pancreatic cancer (Phase IIB / IIIA)
- Klinikum der Ruhr-Universität Bochum
- Medizinische Klinik III - Hämatologie/Onkologie
- More details
-
- NORWAY
- Řstlandet
- NOT YET IDENTIFIED - NO
- CP4126-201 : A phase II study of CP-4126 in patients with advanced pancreatic cancer.
- Not yet identified - NO
- More details
-
- CP4126-201 : A phase II study of CP-4126 in patients with advanced pancreatic cancer - NO
- The Norwegian Radium Hospital
- Department of Clinical Cancer Research
- More details
-
- CP4126-201 : A phase II study of CP-4126 in patients with advanced pancreatic cancer - NO
- Ullevĺl universitetssykehus HF
- Oslo University Hospital, Ullevĺl
- More details
-
- Phase II Study Open, Not Randomized to Evaluate the Efficacy and Safety of Neoadjuvant Treatment With Gemcitabine and Erlotinib Followed by Gemcitabine, Erlotinib and Radiotherapy in Patients With Resectable Pancreatic Adenocarcinoma
- Hospital Clínic de Barcelona
- Servicio de Oncología (ICMHO)
- More details
-
- SPAIN
- Comunidad Valenciana
- ALICANTE
- A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer - ES
- Hospital General Universitario de Alicante
- Servicio de Oncología Médica (H.G.U. de Alicante)
- More details
-
- Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer
- Centro Integral Oncológico Clara Campal
- Unidad de tumores digestivos (CIOCC)
- More details
-
- Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer (Phase II) (completed)
- Centro Integral Oncológico Clara Campal
- Unidad de tumores digestivos (CIOCC)
- More details
-
- A Phase II Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets in Tumor Tissue
- Centro Integral Oncológico Clara Campal
- Unidad de tumores digestivos (CIOCC)
- More details
-
- A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer - ES
- Hospital General Universitario Gregorio Marańón
- Servicio de Oncología (H.G.U. Gregorio Marańón)
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of AMG 479 or Placebo in Combination With Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma of the Pancreas (terminated)
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- GAMMA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas - ES (terminated)
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2) - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398 Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer - ES
- Not yet identified - ES
- More details
